Literature DB >> 23070984

Correlation of electrocardiographic changes and myocardial fibrosis in patients with hypertrophic cardiomyopathy detected by cardiac magnetic resonance imaging.

Bong Gun Song1, Hyun Suk Yang, Hweung Kon Hwang, Gu Hyun Kang, Yong Hwan Park, Woo Jung Chun, Ju Hyeon Oh.   

Abstract

BACKGROUND: Despite several electrophysiologic and pathologic studies, the cause of electrocardiographic (ECG) changes in patients with hypertrophic cardiomyopathy (HCM) remains unclear. Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging can detect myocardial fibrosis. We aimed to assess the relationship between ECG findings and LGE in such patients. HYPOTHESIS: Myocardial LGE may be associated with ECG changes in HCM.
METHODS: Seventy consecutive patients with HCM (mean age, 55.5 ± 10.7 years; 47 males) underwent CMR and 12-lead ECG. The subjects were divided into 3 groups according to the type of hypertrophy: the asymmetric septal hypertrophy group (ASH group, n = 31), the apical hypertrophy group (AP group, n = 22), and concentric hypertrophy group (CH group, n = 17). The transmural and segmental extent, pattern, and location of myocardial LGE were assessed and analyzed in relation to ECG changes.
RESULTS: All of the subjects showed some degree of LGE on CMR. The AP group showed significantly higher prevalence of negative T-wave (P = 0.028) and deep negative T-wave inversion (P = 0.001) than the ASH and CH groups. The total volume of LGE did not show any significant association with ECG changes. LGE detected at the interventricular septum was associated with increased QRS duration (P = 0.009) and was found in 94% of the ASH group, 59% of the AP group, and 77% of the CH group. LGE at the apex of the heart was present in 32% of the ASH group, 73% of the AP group, and 35% of the CH group and was also associated with negative T-wave (P = 0.006) and deep negative T-wave inversion (P = 0.018). Multifocal LGE lesions were associated with increased QRS duration (P = 0.039) as opposed to single nodular or patchy pattern of presence.
CONCLUSIONS: The location of myocardial LGE in HCM shows significant association with various ECG changes. This may be useful information for initially evaluating subjects with HCM and adds pathophysiological insight into understanding ECG changes in myocardial diseases that cannot be explained otherwise.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070984      PMCID: PMC6649432          DOI: 10.1002/clc.22062

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

Review 1.  Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?

Authors:  Li Zhang; Obinna Mmagu; Liwen Liu; Dayuan Li; Yuxin Fan; Adrian Baranchuk; Peter R Kowey
Journal:  World J Cardiol       Date:  2014-08-26

2.  Clinical Characteristics and Prognosis of End-stage Hypertrophic Cardiomyopathy.

Authors:  Yan Xiao; Kun-Qi Yang; Yan-Kun Yang; Ya-Xin Liu; Tao Tian; Lei Song; Xiong-Jing Jiang; Xian-Liang Zhou
Journal:  Chin Med J (Engl)       Date:  2015-06-05       Impact factor: 2.628

3.  Relationship between electrocardiographic findings and Cardiac Magnetic Resonance phenotypes in patients with Hypertrophic Cardiomyopathy.

Authors:  Matteo Fronza; Claudia Raineri; Adele Valentini; Emilio Maria Bassi; Laura Scelsi; Maria Laura Buscemi; Annalisa Turco; Grazia Castelli; Stefano Ghio; Luigi Oltrona Visconti
Journal:  Int J Cardiol Heart Vasc       Date:  2016-03-02

4.  Correlation of Electrocardiographic Changes with Cardiac Magnetic Resonance Findings in Patients with Hypertrophic Cardiomyopathy.

Authors:  Gabriela Miana de Mattos Paixão; Horácio Eduardo Veronesi; Halsted Alarcão Gomes Pereira da Silva; José Nunes de Alencar Neto; Carolina de Paulo Maldi; Luciano de Figueiredo Aguiar Filho; Ibrahim Masciarelli Francisco Pinto; Francisco Faustino de Albuquerque Carneiro de França; Edileide de Barros Correia
Journal:  Arq Bras Cardiol       Date:  2018-01       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.